[Middle-molecule uremic toxins: A renewed interest]

Area of Science:

• Nephrology
• Cardiology
• Toxicology

Background:

• Cardiovascular mortality is a significant issue in chronic kidney disease (CKD).
• Uremic toxins, particularly middle molecular weight molecules, contribute to CKD-related cardiovascular mortality by promoting chronic inflammation.
• Identified uremic toxins linked to cardiovascular risk include FGF23, cytokines, pentraxin-3, and light chains.

Purpose of the Study:

• To explore the role of uremic toxins in cardiovascular mortality among CKD patients.
• To evaluate the potential of new medium cut-off (MCO) hemodialysis membranes in managing uremic toxins and associated cardiovascular risks.

Main Methods:

• Review of epidemiological studies on uremic toxins, inflammation, oxidative stress, and cardiovascular mortality in CKD.
• Discussion of emerging therapeutic strategies, including novel hemodialysis membranes.

Main Results:

• Established link between uremic toxins, chronic inflammation, and cardiovascular mortality in CKD.
• Current therapies like anti-oxidative treatments and antibodies have shown limited benefit.
• Medium cut-off (MCO) membranes show promise for removing middle molecule uremic toxins without significant albumin loss.

Conclusions:

• Uremic toxins are key contributors to cardiovascular mortality in CKD patients.
• Medium cut-off (MCO) hemodialysis membranes represent a potential advancement in managing uremic toxins.
• Further studies are required to validate the efficacy of MCO membranes in reducing morbidity and mortality in dialysis patients.